Clofutriben - Sparrow pharmaceuticals
Alternative Names: SPI-62Latest Information Update: 29 Sep 2025
At a glance
- Originator Sparrow Pharmaceuticals
- Class Antihyperglycaemics; Antirheumatics; Obesity therapies; Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Yes - Cushing syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adrenal gland disorders; Cushing syndrome; Polymyalgia rheumatica; Type 2 diabetes mellitus
- No development reported Diabetic neuropathies; Obesity
Most Recent Events
- 24 Sep 2025 Phase-II clinical trials in Type 2 diabetes mellitus (Treatment-resistant) (PO), prior to September 2025
- 04 Sep 2025 Chemical structure information added.
- 12 Jul 2025 Efficacy and adverse event data from the phase II RESCUE trial in Cushing syndrome presented at the 107th Annual Meeting of the Endocrine Society (ENDO-2025)